Sitewide Sale: Create a Free Seeking Alpha Account
Join the world's leading investor community and get 20% off your first year of any Seeking Alpha service.

or
By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy

JAZZ Jazz Pharmaceuticals plc
Stock Price & Overview

$109.443.32 (+3.13%)4:00 PM 07/01/25
NASDAQ | $USD | Post-Market: $108.00 -1.44 (-1.32%) 5:24 PM

JAZZ Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Latest Headlines

Ratings Summary

People Also Follow

Similar to JAZZ

ETFs Holding JAZZ

JAZZ Company Profile

Jazz Pharmaceuticals plc logo
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Employees
2,800
Founded
2003
Address
  • Waterloo Exchange
  • Fifth Floor
  • Waterloo Road
  • Dublin 4
  • Dublin, D04 E5W7
  • Ireland
Phone Number
353 1 634 7800

JAZZ Revenue

JAZZ Earnings Per Share

Earnings Estimates

Earnings Revisions

Valuation

Growth

Profitability

Momentum

Capital Structure

Dividends

JAZZ Ownership

JAZZ Peers

Risk

Technicals

JAZZ Transcripts

Investor Presentations

JAZZ SEC Filings

JAZZ Income Statement

JAZZ Balance Sheet

JAZZ Cash Flow Statement

JAZZ Long Term Solvency

Jazz Pharmaceuticals plc (JAZZ) Frequently Asked Questions